<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969137</url>
  </required_header>
  <id_info>
    <org_study_id>0905005103</org_study_id>
    <secondary_id>R03DA027474</secondary_id>
    <secondary_id>DCNBR / CNB</secondary_id>
    <nct_id>NCT00969137</nct_id>
  </id_info>
  <brief_title>Sensitivity to Intravenous Nicotine: Genetic Moderators</brief_title>
  <official_title>Sensitivity to Intravenous Nicotine: Genetic Moderators</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the mu opioid receptor gene (OPRM1) A118G polymorphism moderates the&#xD;
      subjective-rewarding effects of intravenous (IV) nicotine in male and female smokers. The&#xD;
      subjective effects of nicotine will be measured with a Drug Effects Questionnaire, including&#xD;
      the ratings of &quot;good effects&quot; and &quot;drug liking&quot;. We hypothesize that smokers with the AG/GG&#xD;
      genotype for the OPRM1 A118G will have attenuated subjective-rewarding effects from IV&#xD;
      nicotine when compared to those with AA genotype.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Increasing evidence suggest that MOR contribute to nicotine's rewarding effect. Further, the&#xD;
      functional OPRM1 A118G variant has been linked to rewarding effects of alcohol in alcohol&#xD;
      users and to nicotine in female smokers. Since no previous studies examined the influence of&#xD;
      the A118G variation on pure nicotine responses, the next logical step is to evaluate how this&#xD;
      genetic polymorphism affects nicotine's rewarding, cognitive, and physiological effects using&#xD;
      IV nicotine administration in male and female smokers. In addition, the association of the&#xD;
      G398A polymorphism of the CHRNA5 gene (rs16969968) with maximal response to nicotinic&#xD;
      agonists justifies examination of this SNP as a moderator of IV nicotine sensitivity in&#xD;
      humans (Bierut et al. 2008). This SNP will be examined in an exploratory fashion since it is&#xD;
      not feasible to fully stratify the study sample for multiple SNPs. The frequency of&#xD;
      rs16969968 SNP ranges from 35%-42% among those of European ancestry, making it feasible to&#xD;
      examine this variation in our subject sample.&#xD;
&#xD;
      Currently this study is active and enrollment is continuing. Currently there are 205&#xD;
      completers and on going.(June 2014)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2, 2009</start_date>
  <completion_date type="Actual">June 1, 2016</completion_date>
  <primary_completion_date type="Actual">June 1, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>primary hypotheses will test the influence of OPRM1 A118G status on subjective responses to IV nicotine, which will be measured with the drug effects questionnaire (DEQ).</measure>
    <time_frame>Injections 30 minutes apart</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Nicotine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravenous Nicotine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline</intervention_name>
    <description>intravenous saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Intravenous nicotine</description>
    <arm_group_label>Nicotine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female and male smokers, aged 18 to 50 years;&#xD;
&#xD;
          -  History of smoking daily for the past 12 months, 10-25 cigarettes daily;&#xD;
&#xD;
          -  Not seeking treatment at the time of the study for nicotine dependence;&#xD;
&#xD;
          -  Have a FTND score of at least 5 and CO level &gt; 10ppm;&#xD;
&#xD;
          -  In good health as verified by medical history, screening examination, and screening&#xD;
             laboratory tests;&#xD;
&#xD;
          -  For women, not pregnant as determined by pregnancy screening, nor breast feeding, and&#xD;
             using acceptable birth control methods.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of major medical illnesses that the physician investigator deems as&#xD;
             contraindicated for the patient to be in the study;&#xD;
&#xD;
          -  Regular use of psychotropic medication (antidepressants, antipsychotics, or&#xD;
             anxiolytics) and recent psychiatric diagnosis and treatment for Axis I disorders&#xD;
             including major depression, bipolar affective disorder, schizophrenia or panic&#xD;
             disorder;&#xD;
&#xD;
          -  Abuse of alcohol or any other recreational or prescription drugs.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mehmet Sofuoglu, M.D,Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Veterans Affairs</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2009</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Mehmet Sofuoglu</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>smoking, nicotine, cigarettes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

